Public companies listed on major exchanges like Nasdaq face ongoing requirements to stay in good standing. One of the most basic rules involves the minimum bid price, which must close at $1.00 or higher for listed stocks. Companies that fall below this level for 30 consecutive business days receive a deficiency notice from the exchange, marking the start of a compliance process.
Failure to meet these standards does not lead to immediate removal from the exchange. Instead, Nasdaq and similar markets follow a structured path that gives the company a chance to fix the issue. If the stock price does not recover, trading can eventually shift to over-the-counter markets, which often carry less visibility and liquidity for investors.
The cure period typically begins with 180 calendar days for the company to show its shares closing at or above $1.00 for 10 consecutive business days. Should that window close without success, the exchange may grant a second 180-day extension, provided the company meets other listing criteria like market value and shareholder equity. This stepwise approach allows management time to explore options such as improving operations or adjusting the share structure.
Curanex Pharmaceuticals Inc. (NASDAQ: CURX) serves as a clear example of this process in action. The company first fell out of compliance with the $1 bid price rule after 30 business days below the threshold ending in late 2025, triggering its initial notice on November 5, 2025. That started a 180-day clock to regain the standard, which expired on May 4, 2026, without the stock meeting the 10-day requirement.
Nasdaq then approved an additional 180-day period for Curanex, now extending compliance efforts until November 2, 2026. During this time, the company intends to monitor its stock price and consider measures like a reverse stock split if market conditions do not lift the shares naturally. Reverse splits reduce the number of outstanding shares to boost the per-share price, helping meet technical rules without altering overall company value.
For small biotechnology firms like Curanex, a micro-cap player focused on drug development, these listing hurdles create real pressure beyond daily operations. Investors in this space often see sharp price swings tied to compliance news, as the risk of delisting affects access to institutional buyers and traditional trading platforms. Even with a solid pipeline, the focus shifts to survival mechanics during these periods.
This regulatory lifeline reflects how exchanges balance investor protection with opportunities for recovery. Companies must file updates with the SEC through Form 8-K to disclose these events, keeping shareholders informed. Curanexs extension buys critical breathing room, but success hinges on either organic price recovery or decisive action before the final deadline.
The Curanex case underscores a routine yet high-stakes reality for micro-caps. Nasdaq provides these extensions to avoid hasty delistings, yet the market responds quickly to every milestone. Shareholders now await whether shares can sustain $1.00 or if restructuring steps come next, shaping the stocks path through late 2026.
